{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:06Z","timestamp":1784945826928,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vascular endothelial growth factor (VEGF) is key to wet age-related macular degeneration (wAMD). Anti-VEGF drugs are the main treatment in clinics. This study assessed ocular adverse events (AE) from anti-VEGF drugs in VigiAccess, WHO\u2019s database, and compared adverse drug reaction (ADR) profiles of four drugs to aid personalized treatment choices for optimal benefit and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The design was a descriptive retrospective study. We observed four anti-VEGF drugs commonly used in the clinical treatment of wAMD, and their ADR reports came from WHO-VigiAccess. The collected data included the age group, gender, and regional data, as well as the data of disease systems and symptoms caused by ADR recorded in the annual ADR reports and reports received by the WHO. We observed the overall characteristics of the ADR reports of these drugs, then explored the distribution of 27 SOCs of these drugs. Subsequently, we compared the most common ocular ADRs of the drugs. Finally, we compared the commonalities and differences of ocular ADRs related to the drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 57,779 AE associated with the four anti-VEGF drugs were reported. The results showed that the number of females experiencing ADRs (67.83%) was significantly higher than males (32.17%), the age group with the highest reported incidence was over 75\u00a0years old. More than half of the ADR reports came from the Americas (50.86%). The five most common types of AE were: eye disorders (43.56%), general disorders and administration site conditions (34.47%), injury poisoning and procedural complications (13.36%), infections and infestations (11.61%), nervous system disorders (9.99%). Compared with the other three inhibitors, brolucizumab had a significantly higher rate of ocular ADR reports. The most common ocular ADRs of these four anti-VEGF drugs were mostly related to visual impairment, vision blurred, and blindness. However, there is still a disparity of ADRs between different drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The presence of ocular AEs when using anti-VEGF drugs to treat wAMD in clinical practice should attract clinical attention. Clinicians should use these expensive drugs more rationally based on the characteristics of ADRs and develop personalized treatment plans for patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1398783","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:25:45Z","timestamp":1722313545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study"],"prefix":"10.3389","volume":"15","author":[{"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int. J. Retina Vitr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/ijms21155294","article-title":"VEGF-A in cardiomyocytes and heart diseases","volume":"21","author":"Braile","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000529930","article-title":"Old problem in a new guise: retinal pigment epithelium tear after intravitreal faricimab (Vabysmo\u00ae) injection","volume":"14","author":"Clemens","year":"2023","journal-title":"Case Rep. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000439445","article-title":"Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring","volume":"235","author":"Clemens","year":"2016","journal-title":"Ophthalmologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40264-017-0553-y","article-title":"Overview of the safety of anti-VEGF drugs: analysis of the Italian spontaneous reporting system","volume":"40","author":"Cutroneo","year":"2017","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/pharmaceutics14112328","article-title":"Real-world safety profile of biologics used in rheumatology: a six-year observational pharmacovigilance study in the calabria region","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/pds.5249","article-title":"Pharmacovigilance network as an additional tool for the surveillance of antimicrobial resistance","volume":"30","author":"Habarugira","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12032-017-1049-4","article-title":"Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA","volume":"34","author":"Ivanova","year":"2017","journal-title":"Med. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"eabq5241","DOI":"10.1126\/scitranslmed.abq5241","article-title":"Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events","volume":"15","author":"Karle","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","article-title":"Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy","volume":"65","author":"Kataoka","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"eabq5068","DOI":"10.1126\/scitranslmed.abq5068","article-title":"A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab","volume":"15","author":"Kearns","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.ajoc.2022.101521","article-title":"Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation","volume":"26","author":"Kusuhara","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.11.5.22","article-title":"Sex and age-related differences in complement factors among patients with intermediate age-related macular degeneration","volume":"11","author":"Marin","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3928\/23258160-20190503-05","article-title":"Inflammatory reaction after aflibercept intravitreal injections associated with silicone oil droplets released from syringes: a case-control study","volume":"50","author":"Melo","year":"2019","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"B25","doi-asserted-by":"publisher","first-page":"324841","DOI":"10.1155\/2015\/324841","article-title":"Ranibizumab for visual impairment due to diabetic macular edema: real-world evidence in the Italian population (PRIDE study)","volume":"2015","author":"Menchini","year":"2015","journal-title":"J. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1167\/iovs.13-11821","article-title":"Fc\u03b3 receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration","volume":"55","author":"Murinello","year":"2014","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41433-022-02008-3","article-title":"The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice","volume":"36","author":"Pearce","year":"2022","journal-title":"Eye (Lond)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1007\/s10792-023-02767-2","article-title":"Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration","volume":"43","author":"Shome","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","article-title":"Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis","volume":"23","author":"Souied","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2008.10.005","article-title":"Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration","volume":"147","author":"Spaide","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye (Lond)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/jcm13010295","article-title":"Ranibizumab modifies the expression of metalloproteinases and their tissue inhibitors in peripheral blood mononuclear cells in patients with exudative age-related macular degeneration","volume":"13","author":"Strzalka-Mrozik","year":"2024","journal-title":"J. Clin. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1371\/journal.pone.0059092","article-title":"The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children","volume":"26","author":"Tantikul","year":"2008","journal-title":"Asian Pac J. Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","article-title":"Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from lareb and Uppsala monitoring centre","volume":"41","author":"Watson","year":"2018","journal-title":"Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration","volume":"115","author":"Wickremasinghe","year":"2008","journal-title":"Ophthalmology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2109365","DOI":"10.1080\/21645515.2022.2109365","article-title":"Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: a descriptive analysis from VigiAccess","volume":"18","author":"Yamoah","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14740338.2023.2250717","article-title":"A real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System","volume":"4","author":"Zhou","year":"2023","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1398783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:25:50Z","timestamp":1722313550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1398783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":41,"alternative-id":["10.3389\/fphar.2024.1398783"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1398783","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1398783"}}